Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

4Total
P 1 (1)
P 2 (2)
P 3 (1)

Trial Status

Completed2
Suspended1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 2 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT06451757Phase 3Recruiting

KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases

NCT04846036Phase 2Suspended

The KHENERGYC Study

NCT04604548Phase 2Completed

The KHENEREXT Study

NCT02544217Phase 1Completed

A Dose-escalating Clinical Trial With KH176

Showing all 4 trials

Research Network

Activity Timeline